EMA explains environmental risk assessment rules for human drugs
This article was originally published in SRA
The European Medicines Agency has issued a question & answer document on its current guideline on environmental risk assessment of human medicines1,2. The document, from the EMA's scientific working party, is designed to clarify some issues relating to the guideline and to help harmonise the way in which it is interpreted.
You may also be interested in...
New treatments for advanced endometrial cancer and hereditary angioedema are among six drugs that have just been recommended for EU-wide approval. Harmonized EU advice has also been issued in relation to an investigational antibody combination for treating COVID-19.
As part of its big data initiative, the European Medicines Agency is supporting projects that will help identify appropriate real-world data sources for regulatory decision making.
The European Medicines Agency may decide this week on a dozen requests by companies seeking new uses of their approved drugs.